Literature DB >> 11209937

Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death.

J van Beek1, O Nicole, C Ali, A Ischenko, E T MacKenzie, A Buisson, M Fontaine.   

Abstract

The anaphylatoxin C3a is a potent inflammatory polypeptide released at sites of complement activation. To test whether C3a might alter neuronal outcome following an ischemic insult, we determined the effects of purified human C3a on murine primary cortical cell cultures exposed to apoptotic or excitotoxic paradigms. C3a prevented neither serum deprivation-induced apoptotic neuronal death, nor AMPA/kainate-mediated excitotoxicity. However, in mixed cultures of neurons and astrocytes, C3a dose-dependently protected neurons against NMDA toxicity (47% neuroprotection using 100 nM C3a, p < 0.01, n = 12). The neuroprotective effect of C3a was observable only in the presence of astrocytes. These observations suggest that C3a is involved in excitotoxicity-mediated neuronal death through astrocyte stimulation and extend its role beyond immune functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11209937     DOI: 10.1097/00001756-200102120-00022

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  43 in total

Review 1.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

Review 2.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

Review 3.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

Review 4.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 5.  Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments.

Authors:  Paul M George; Gary K Steinberg
Journal:  Neuron       Date:  2015-07-15       Impact factor: 17.173

6.  Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.

Authors:  Noriko Shinjyo; Yolanda de Pablo; Milos Pekny; Marcela Pekna
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

Review 7.  CR1 in Alzheimer's disease.

Authors:  Xi-Chen Zhu; Jin-Tai Yu; Teng Jiang; Ping Wang; Lei Cao; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

8.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

Review 9.  Complement in multiple sclerosis: its role in disease and potential as a biomarker.

Authors:  G Ingram; S Hakobyan; N P Robertson; B P Morgan
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

10.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.